Surfacing role of probiotics in cancer prophylaxis and therapy: A systematic review

Dasari, Subramanyam; Kathera, Chandrasekhar; Janardhan, Avilala; Kumar, Ajeet; Viswanath, Buddolla

doi:10.1016/j.clnu.2016.11.017

Cited by 61 publications

(37 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, L. acidophilus increased antitumor effect of cisplatin and increased survival rates of C57BL/6 mice with lung cancer (Gui et al, 2015). In another study, Enterococcus hirae and Barnesiella intestinihominis increased cyclophosphamide-anticancer effects in mice with advanced lung cancer through promoting the infiltration of IFN-γ-producing γδT cells in cancer lesions (Dasari et al, 2017).…”

Section: Acting As Probiotics and Prebioticsmentioning

confidence: 96%

The Cross-Talk Between Gut Microbiota and Lungs in Common Lung Diseases

et al. 2020

View full text Add to dashboard Cite

Emerging findings indicate there is a vital cross-talk between gut microbiota and the lungs, which is known as gut-lung axis. The gut disturbances in lung diseases including allergy, asthma, chronic obstructive pulmonary disease, cystic fibrosis and lung cancer were observed by extensive studies. Investigating how gut microbiota impact other distant organs is of great interest in recent years. Although it has not been fully understood whether the disturbance is the cause or effect of lung diseases, alterations in the gut microbial species and metabolites have been linked to changes in immune responses and inflammation as well as the disease development in the lungs. In this article, we systemically review the role and mechanisms underlying the changes in the constituent of gut microbiota and metabolites in lung diseases. In particular, the roles of gut-lung axis in mediating immune responses and reshaping inflammation are highlighted. Furthermore, we discuss the potential of strategies to manipulate the gut microbiota and metabolites as the therapeutic approach for lung diseases.

show abstract

Section: Acting As Probiotics and Prebioticsmentioning

confidence: 96%

The Cross-Talk Between Gut Microbiota and Lungs in Common Lung Diseases

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Indeed, this early colonization of the gut by bifidobacteria and propionibacteria seems to prevent necrotizing enterocolitis (Colliou et al, 2017; Young et al, 2017). In addition, the manipulation of the gut microbiota with probiotics has been considered as a possible manner to prevent and treat obesity and cancers (Saez-Lara et al, 2015; Dasari et al, 2017; Rabah et al, 2017; Brusaferro et al, 2018). Propionibacterium freudenreichii inhibits pathogens such as Salmonella Heidelberg (Nair FIM 2018) and meticillin-resistant Staphylococcus aureus (Sikorska and Smoragiewicz, 2013).…”

Section: Beneficial Effects Of Propionibacteria Bifidobacteria and Lmentioning

confidence: 99%

Review: Adaptation of Beneficial Propionibacteria, Lactobacilli, and Bifidobacteria Improves Tolerance Toward Technological and Digestive Stresses

Bonnassié

Rabah

Marchand³

et al. 2019

Front. Microbiol.

View full text Add to dashboard Cite

This review deals with beneficial bacteria, with a focus on lactobacilli, propionibacteria, and bifidobacteria. As being recognized as beneficial bacteria, they are consumed as probiotics in various food products. Some may also be used as starters in food fermentation. In either case, these bacteria may be exposed to various environmental stresses during industrial production steps, including drying and storage, and during the digestion process. In accordance with their adaptation to harsh environmental conditions, they possess adaptation mechanisms, which can be induced by pretreatments. Adaptive mechanisms include accumulation of compatible solutes and of energy storage compounds, which can be largely modulated by the culture conditions. They also include the regulation of energy production pathways, as well as the modulation of the cell envelop, i.e., membrane, cell wall, surface layers, and exopolysaccharides. They finally lead to the overexpression of molecular chaperones and of stress-responsive proteases. Triggering these adaptive mechanisms can improve the resistance of beneficial bacteria toward technological and digestive stresses. This opens new perspectives for the improvement of industrial processes efficiency with regard to the survival of beneficial bacteria. However, this bibliographical survey evidenced that adaptive responses are strain-dependent, so that growth and adaptation should be optimized case-by-case.

show abstract

“…[ 16 ] For Gram‐positive bacteria without LPS and flagellum, such as Bifidobacterium , it could activate macrophages, natural killer (NK) cells, DCs and B lymphocytes by peptidoglycan, extracellular polysaccharides and DNA. [ 17 ] Then, these effector cells could be promoted to produce immune active substances, such as IL‐1, IL‐6, IL‐12, TNF‐ α , IFN‐ γ , and nitric oxide (NO), and finally facilitate the anti‐tumor effect. [ 18 ] Therefore, it seems that bacteria and cancer immunotherapy will inevitably be combined ( Figure ).…”

Section: Introductionmentioning

confidence: 99%

Bacteria‐Based Cancer Immunotherapy

et al. 2021

View full text Add to dashboard Cite

In the past decade, bacteria‐based cancer immunotherapy has attracted much attention in the academic circle due to its unique mechanism and abundant applications in triggering the host anti‐tumor immunity. One advantage of bacteria lies in their capability in targeting tumors and preferentially colonizing the core area of the tumor. Because bacteria are abundant in pathogen‐associated molecular patterns that can effectively activate the immune cells even in the tumor immunosuppressive microenvironment, they are capable of enhancing the specific immune recognition and elimination of tumor cells. More attractively, during the rapid development of synthetic biology, using gene technology to enable bacteria to be an efficient producer of immunotherapeutic agents has led to many creative immunotherapy paradigms. The combination of bacteria and nanomaterials also displays infinite imagination in the multifunctional endowment for cancer immunotherapy. The current progress report summarizes the recent advances in bacteria‐based cancer immunotherapy with specific foci on the applications of naive bacteria‐, engineered bacteria‐, and bacterial components‐based cancer immunotherapy, and at the same time discusses future directions in this field of research based on the present developments.

show abstract

Surfacing role of probiotics in cancer prophylaxis and therapy: A systematic review

Cited by 61 publications

References 84 publications

The Cross-Talk Between Gut Microbiota and Lungs in Common Lung Diseases

The Cross-Talk Between Gut Microbiota and Lungs in Common Lung Diseases

Review: Adaptation of Beneficial Propionibacteria, Lactobacilli, and Bifidobacteria Improves Tolerance Toward Technological and Digestive Stresses

Bacteria‐Based Cancer Immunotherapy

Contact Info

Product

Resources

About